CA2672933A1 - Method of treating cancer by a combined therapy of anticancer agents - Google Patents
Method of treating cancer by a combined therapy of anticancer agents Download PDFInfo
- Publication number
- CA2672933A1 CA2672933A1 CA002672933A CA2672933A CA2672933A1 CA 2672933 A1 CA2672933 A1 CA 2672933A1 CA 002672933 A CA002672933 A CA 002672933A CA 2672933 A CA2672933 A CA 2672933A CA 2672933 A1 CA2672933 A1 CA 2672933A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- rituximab
- cancer
- docetaxel
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 101
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 76
- 201000011510 cancer Diseases 0.000 title claims abstract description 33
- 238000002648 combination therapy Methods 0.000 title claims description 47
- 238000000034 method Methods 0.000 title description 9
- QBIYUDDJPRGKNJ-UHFFFAOYSA-M sepantronium bromide Chemical compound [Br-].O=C1C2=CC=CC=C2C(=O)C2=C1N(CCOC)C(C)=[N+]2CC1=CN=CC=N1 QBIYUDDJPRGKNJ-UHFFFAOYSA-M 0.000 claims abstract description 128
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims abstract description 88
- 229960003668 docetaxel Drugs 0.000 claims abstract description 80
- 229960004641 rituximab Drugs 0.000 claims abstract description 57
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 38
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 229960004562 carboplatin Drugs 0.000 claims abstract description 29
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 29
- 229960004316 cisplatin Drugs 0.000 claims abstract description 29
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 26
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 26
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 25
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 24
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 23
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims abstract description 22
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 22
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims abstract description 19
- 229960003901 dacarbazine Drugs 0.000 claims abstract description 18
- 229960002066 vinorelbine Drugs 0.000 claims abstract description 18
- 229960004768 irinotecan Drugs 0.000 claims abstract description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 13
- 201000005202 lung cancer Diseases 0.000 claims abstract description 12
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 12
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 190000008236 carboplatin Chemical compound 0.000 claims abstract 12
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims abstract 6
- 238000001802 infusion Methods 0.000 claims description 44
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 20
- 230000001093 anti-cancer Effects 0.000 claims description 19
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 19
- 229960001101 ifosfamide Drugs 0.000 claims description 19
- 229960005420 etoposide Drugs 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 15
- 229960000684 cytarabine Drugs 0.000 claims description 12
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 206010009944 Colon cancer Diseases 0.000 abstract description 6
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 5
- 206010060862 Prostate cancer Diseases 0.000 abstract description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 5
- 206010005003 Bladder cancer Diseases 0.000 abstract description 4
- 206010006187 Breast cancer Diseases 0.000 abstract description 4
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract description 4
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 206010017758 gastric cancer Diseases 0.000 abstract description 3
- 201000011549 stomach cancer Diseases 0.000 abstract description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract description 2
- 206010038389 Renal cancer Diseases 0.000 abstract description 2
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 abstract description 2
- 201000010982 kidney cancer Diseases 0.000 abstract description 2
- 229940127084 other anti-cancer agent Drugs 0.000 abstract description 2
- 201000002528 pancreatic cancer Diseases 0.000 abstract description 2
- 201000000849 skin cancer Diseases 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 206010046766 uterine cancer Diseases 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 39
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 27
- 230000037396 body weight Effects 0.000 description 24
- 229940090044 injection Drugs 0.000 description 18
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 239000002504 physiological saline solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- 102000000763 Survivin Human genes 0.000 description 13
- 108010002687 Survivin Proteins 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 230000004614 tumor growth Effects 0.000 description 12
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 12
- 238000011260 co-administration Methods 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 8
- 230000003442 weekly effect Effects 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940063683 taxotere Drugs 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 210000001142 back Anatomy 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108091007065 BIRCs Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 2
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 229940034086 dacarbazine 200 mg Drugs 0.000 description 2
- GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 229940090411 ifex Drugs 0.000 description 1
- 150000004693 imidazolium salts Chemical class 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940039472 irinotecan injection Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007761 synergistic anti-cancer Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a therapeutic composition which contains as an active ingredient, a pharmaceutical, particularly 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide and is applied in combination with one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or R-ICE and R-DHAP, which is a rituximab-containing combination regimen. The composition of the invention is useful for treatment of all solid cancers and lymphomas, preferably skin cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, lung cancer, colon cancer, pancreatic cancer, renal cancer, stomach cancer and the like. In particular, it is expected as a therapeutic agent for cancer resistant to other anticancer agents.
Description
DESCRIPTION
Method of Treating Cancer by a Combined Therapy of Anticancer Agents TECHNICAL FIELD
[0001] The present invention relates to a medicament, especially a pharmaceutical composition comprises 1-(2 -methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro- IH
-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient for treatment of a cancer in a combined therapy with one or more other anticancer agents.
BACKGROUND ART
Method of Treating Cancer by a Combined Therapy of Anticancer Agents TECHNICAL FIELD
[0001] The present invention relates to a medicament, especially a pharmaceutical composition comprises 1-(2 -methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro- IH
-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient for treatment of a cancer in a combined therapy with one or more other anticancer agents.
BACKGROUND ART
[0002] Survivin is a member of the IAP (Inhibitor of Apoptosis) family of proteins, and is highly expressed in all primary tumor types.
Survivin is undetectable in most normal differentiated tissues, but is present in normal placenta, testes, and rapidly dividing cells such as CD34+ bone marrow stem cells.
High expression of survivin in tumors is correlated with poor survival among patients with non-small cell lung cancer (NSCLC) [Ref. 1]. Suppression of survivin induces tumor cell death and renders the cells sensitive to normal cell cycle regulation [Ref. 2 - Ref. 41. Given its preferential expression in tumor cells, its ability to block apoptosis and regulate cancer cell proliferation, and its correlation with poor survival, survivin stands out as a putative novel target for cancer therapy.It has been reported that the down-regulation of survivin expression by the antisense or siRNA of survivin was shown to sensitize tumor cells to various anticancer drugs [Ref. 7 - Ref. 13].
Survivin is undetectable in most normal differentiated tissues, but is present in normal placenta, testes, and rapidly dividing cells such as CD34+ bone marrow stem cells.
High expression of survivin in tumors is correlated with poor survival among patients with non-small cell lung cancer (NSCLC) [Ref. 1]. Suppression of survivin induces tumor cell death and renders the cells sensitive to normal cell cycle regulation [Ref. 2 - Ref. 41. Given its preferential expression in tumor cells, its ability to block apoptosis and regulate cancer cell proliferation, and its correlation with poor survival, survivin stands out as a putative novel target for cancer therapy.It has been reported that the down-regulation of survivin expression by the antisense or siRNA of survivin was shown to sensitize tumor cells to various anticancer drugs [Ref. 7 - Ref. 13].
[0003] Fused condensed imidazolium derivatives which are expected to be candidates for anti-tumor agents having good anti-tumor activity, low toxicity and wide broad safety margins are disclosed in International Publications [Ref. 5 and Ref. 6]. Particularly, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-naph tho[2,3-d]imidazol-3-ium bromide (hereinafter YM155), shown by the following formula, is a compound which is expected to be useful as an anti-tumor agent, because it has good in vivo tumor growth inhibitory activity and low toxicity.
N~
O
+ N
N~Me N
O ~,OMe YM155 is the first compound found to specifically suppress survivin and it has potent anti-tumor activities in experimental human hormone refractory prostate cancer (HRPC) xenograft models [Ref. 141, human NSCLC xenograft models [Ref. 15], and in patients with advanced solid tumors and non-Hodgkin's lymphoma (NHL) [Ref. 16 and Ref. 17]. YM155 showed time-dependent anti-tumor activity, and 7-day continuous infusion of YM155 induced tumor regression in the NSCLC xenograft model [Ref. 15]. YM155 caused fewer side effects, e.g., body weight decrease and hematological toxicities which are frequently observed with paclitaxel, cisplatin and doxorubicin treatment [Ref. 16 and Ref. 17].
N~
O
+ N
N~Me N
O ~,OMe YM155 is the first compound found to specifically suppress survivin and it has potent anti-tumor activities in experimental human hormone refractory prostate cancer (HRPC) xenograft models [Ref. 141, human NSCLC xenograft models [Ref. 15], and in patients with advanced solid tumors and non-Hodgkin's lymphoma (NHL) [Ref. 16 and Ref. 17]. YM155 showed time-dependent anti-tumor activity, and 7-day continuous infusion of YM155 induced tumor regression in the NSCLC xenograft model [Ref. 15]. YM155 caused fewer side effects, e.g., body weight decrease and hematological toxicities which are frequently observed with paclitaxel, cisplatin and doxorubicin treatment [Ref. 16 and Ref. 17].
[0004] In general, there is a limit to efficacy of chemotherapy for tumors, particularly malignant tumors, when an anticancer agent is administered alone, in view of adverse reactions, and it is quite rare to attain a sufficient anticancer effect. In a clinical practice , accordingly, a multi-drug combination therapy in which 2 or more species of drugs having different mechanisms of action are used in combination has been employed. Through combination therapy, reduction of adverse drug reaction and potentiation of the anticancer activity are intended by combination of anticancer agents having different mechanisms of action, including 1) reduction of the non-sensitive cell population, 2) prevention or delaying of occurrence of drug resistance, and 3) dispersing of toxicity by means of a combination of drugs having different toxicities. With combination therapy, however, a random combination of anticancer agents having different mechanisms of action does not necessarily yield a potentiation effect of anticancer activities.
Thus, studies have been conducted to obtain a combination of anticancer agents having a much higher anticancer action.
Representative combinational drugs include, for example, cisplatin and gemcitabine as well as carboplatin and paclitaxel, which are known as standard combination therapy for lung cancer [Ref. 18 and Ref. 191. A randomized phase III study of combination therapies, R-ICE (rituximab, ifosfamide, carboplatin and etoposide) and R-DHAP (rituximab, cisplatin, Cytarabine (ara-C) and dexamethasone) is in progress in patients with lymphoma (DLBCL) [Ref. 20, 21 and 22].
Thus, studies have been conducted to obtain a combination of anticancer agents having a much higher anticancer action.
Representative combinational drugs include, for example, cisplatin and gemcitabine as well as carboplatin and paclitaxel, which are known as standard combination therapy for lung cancer [Ref. 18 and Ref. 191. A randomized phase III study of combination therapies, R-ICE (rituximab, ifosfamide, carboplatin and etoposide) and R-DHAP (rituximab, cisplatin, Cytarabine (ara-C) and dexamethasone) is in progress in patients with lymphoma (DLBCL) [Ref. 20, 21 and 22].
[0005] REFERENCES
1. Monzo M, et al., J Clin Oncol 1999;17:2100-4.
2. Giodini A, et al., Cancer Res 2002;62=2462-7.
3. Mesri M, et al., Am J Pathol 2001;158 :1757-65.
4. Yamamoto T, et al., Med Electron Microsc 2001;34:207-12.
5. Pamphlets of International Publication 01/60803 6. Pamphlets of International Publication 2004/092160 7. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8 8. Cancer Lett. 2006 Feb 8;232(2):243-54 9. Blood. 2006 Feb 15;107(4):1555-63. Epub 2005 Oct 27 10. Int. J. Cancer: 118, 812-20 (2006) 11. J Clin Invest. 2001 Oct;108(7):981-90.
1. Monzo M, et al., J Clin Oncol 1999;17:2100-4.
2. Giodini A, et al., Cancer Res 2002;62=2462-7.
3. Mesri M, et al., Am J Pathol 2001;158 :1757-65.
4. Yamamoto T, et al., Med Electron Microsc 2001;34:207-12.
5. Pamphlets of International Publication 01/60803 6. Pamphlets of International Publication 2004/092160 7. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8 8. Cancer Lett. 2006 Feb 8;232(2):243-54 9. Blood. 2006 Feb 15;107(4):1555-63. Epub 2005 Oct 27 10. Int. J. Cancer: 118, 812-20 (2006) 11. J Clin Invest. 2001 Oct;108(7):981-90.
12. Prostate 65,10-19 (2005) 13. The Prostate 64:293-302 (2005) 14. Proceedings AACR-NCI-EORTC 2005, Abstract #B203.
15. Proc Amer Assoc Cancer Res 2006; 47=[Abstract #5671]
16. Annals of Oncology, 2006; 17(Suppl. 3):23, Abstract #0.403.
17. Journal of Clinical Oncoclogy, 2006:ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), Abstract #3014.
18. Cancer, 1996, 77:2458-63.
19. Cancer, 2000, 89:1714-9.
20. Annals of Oncology, 2006; 17(Suppl. 4):iv3l-2.
21. Blood. 2006 May 15;103(10):3684-8. Epub 2004 Jan 22.
22. Leukemia & Lymphoma 2007 May ;48(5):897-904.
DISCLOSURE OF THE INVENTION
Problems that the Invention is to Solve [0006] When the combinational drugs are used together, there are a lot of cases where the side effects increase as well as the anti-tumor effects.
Therefore there are many difficulties in combining two or more anti-tumor agents.
Especially, a combination of anticancer agents with a synergistic anticancer action resulting in marked reduction of cancer cells and further complete removal of the cancer cells, leading to a complete cure of cancer without an increase of side effects, is eagerly desired.
Means for Solving the Problems [0007] The present inventors have found that a combination use of 1-(2 -methoxyethyl)-2 -methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-lH-naph tho[2,3-d]imidazol-3-ium bromide (YM155) with an existing anticancer agent or agents, particularly, docetaxel or rituximab, unexpectedly potentiates the anticancer effect. Thus, the present invention was completed.
That is, the present invention relates to a pharmaceutical composition comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient, for treating cancer in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin (CBDCA), cisplatin (CDDP), paclitaxel (TXL), vinorelbine (VIN), gemcitabine (GEM), irinotecan (CPT-11), docetaxel (TXT), doxorubicin (DXR), dacarbazine (DTIC) and rituximab(RTX), or ii) a rituximab-containing combination therapy selected from R-ICE (consisting of rituximab, ifosfamide (IFM), carboplatin and etoposide (ETP)), and R-DHAP
(consisting of rituximab, cytarabine (ara-C) and cisplatin as anticancer, agents).
Usually, R-DHAP contains dexamethasone as an agent for treatment of chemotherapy-induced nausea and vomiting in addition to the above-mentioned anti-cancer drugs.
[0008] In the invention, the preferable compositions are as follows:
(1) The composition as described above, wherein the combined therapy comprises the use of docetaxel or paclitaxel.
(2) The composition as described in (1), wherein the combined therapy comprises the use of docetaxel.
(3) The composition as described in (2), wherein the composition is for treating hormone-resistant prostate cancer.
(4) The composition as described above, wherein the composition is for treating lung cancer and the combined therapy comprises the use of one or more agents selected from docetaxel, paclitaxel, carboplatin, cisplatin and gemcitabine.
(5) The composition as described above, wherein the combined therapy comprises the use of rituximab.
(6) The composition as described above, wherein the combined therapy comprises the use of a combination therapy selected from R-ICE and R-DHAP.
(7) The composition as described in (6), wherein the combined therapy comprises the use of a combination therapy R-ICE.
(8) The composition as described in (5) or (6), wherein the composition is for treating lymphoma.
(9) The composition as described above, wherein the composition is a formulation for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-nap htho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 1 -mg/m2/day continuously for a period of 4 - 14 days.
(10) A composition as described in (9), wherein the formulation is for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl) -4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 3 - 8 mg/m2/day continuously for 7 days, followed by drug holidays of 14 days, which administration cycle as one cycle is repeated depending on the conditions.
[0009] The present invention also relates to the following inventions:
(11) Use of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl) -4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide for production of a medicament for treating cancer, wherein the medicament is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP.
(12) An agent for cancer treatment comprising as an active ingredient 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide, wherein the agent is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP.
(13) A potentiator of an anticancer effect of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP, wherein the potentiator comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient.
(14) A kit comprising at least one cycle dosage of 1-(2-methoxyethyl)-2 -methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-nap htho[2,3-d]imidazol-3-ium bromide and i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) anticancer agents for a combination therapy selected from R-ICE and R-DHAP.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 contains graphs showing the results of Test Examples 1 and 2 in which YM155 was administered in combination with docetaxel. (a) -(c) are graphs respectively showing the tumor volume (mm3) in Test Example 1, Test Example 2B) and Test Example 2A); (d) - (f) are graphs respectively showing body weight (g) in Test Example 1, Test Example 2B) and Test Example 2A).
Figure 2, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and carboplatin (CBDCA) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and cisplatin (CDDP) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 3, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and gemicitabine (GEM) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and vinorelbine (VIN) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 4, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and doxorubicin (DXR) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and irinotecan (CPT-11) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 5, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and paclitaxel (TXL) in Test Example 3, and (b) shows the mean body weight (g), respectively.
Figure 6, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and Dacarbazine (DTIC) in Test Example 4, and (b) shows the mean body weight (g), respectively.
Figure 7, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and R-ICE (RICE) in Test Example 5, and (b) shows the mean body weight (g), respectively. And (c) shows the mean tumor volume (mm3) from co-administration of YM155 and Rituximab (RTX) in Test Example 5, and (d) shows the mean body weight (g), respectively.
BEST MODE FOR CARRYING OUT OF THE INVENTION
[0011] The following describes the invention in detail.
YM155 used in the invention is readily available according to the processes of production as disclosed in International Publication 01/60803 and International Publication 2004/092160.
YM155 may be administered orally or parenterally, and preferably intravenously. In this connection, the injection preparation for intravenous administration includes those containing sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The aqueous solvent includes, for example, distilled water for injection and physiological saline. The non-aqueous solvent includes, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 (trade name), and the like. Such compositions may contain further tonicity adjusting agents, antiseptics, moistening agents, emulsifying agents, dispersing agents, stabilizers, and solubilizing agents.
These may be sterilized, for example, by filtration through a bacterial filter, blending of sterilizers or irradiation. Alternatively, it is possible to prepare a germ-free solid composition and dissolve or suspend it in sterile water or a sterile solvent for injection immediately before use.
[0012] In intravenous administration, YM155 may be administered usually at 0.1 - 20 mg/m2/day, preferably at 1- 10 mg/m2/day, once a day or divided in plural doses, or continuously by infusion (continuous instillation).
Preferably, it may be infused at 3 - 10 mg/m2/day continuously for a period of 4 days to 20 days, more preferably 4 days to 14 days, or 5 days, 7 days, 10 days or 14 days, and yet more preferably infused continuously for 7 days. When the administration is further continued, it is preferable to employ a medication cycle comprising a term of drug holidays of 1 day to 2 months, preferably 7 days to 21 days, more preferably 14 days, after termination of the above term of medication. In a particularly preferred embodiment, it may be administered continuously by infusion at a dose of 3 - 8 mg/m2/day for 7days, followed by drug holidays of 14 days; this cycle as one cycle is repeated depending on the conditions. When an anticancer agent used in combination has a particular medication cycle, it is preferable to establish a medication cycle for YM155 and said anticancer agent so that potentiation is attained. Specifically, the frequency of administration, dosage, time of infusion, medication cycle, and the like, may be determined properly according to individual cases considering the kind of anticancer agent, state of the patients, age, gender, etc.
[0013] The following table lists existing anticancer agents suitable for combination use with YM155 of the invention, together with the main indications of cancer. The cancers indicated for these anticancer agents in the combined therapy of the invention is not limited to these cancers.
[Table 1) Anticancer Agent Main Indications of Cancer Carboplatin CBDCA colon cancer, lung cancer Cisplatin CDDP colon cancer, lung cancer Paclitaxel TXL lung cancer, ovary cancer Vinorelbine VNR lung cancer Gemcitabine GEM lung cancer, pancreas cancer, colon cancer Irinotecan CPT- 11 colon cancer Docetaxel TXT prostate cancer, lung cancer Doxorubicin DXR bladder cancer Dacarbazine DTIC malignant melanoma Rituximab RTX CD20-positive B-cell non-Hodgkin's lymphoma Third line chemotherapy of germ cell testicular Ifosfamide IFM cancer when used in combination with certain other approved antineoplastic agents In combination with other approved Etoposide ETP chemotherapeutic agents as first line treatment in patients with small cell lung cancer.
Cytarabine ara-C Leukemia [0014] The above-mentioned anticancer agents have already been used clinically, and their administration route, administration cycle, and dose are apparent for a person skilled in the art. The appropriate dosage and administration are different depending on the species of cancer, condition and combinational agents.
Detailed information is available from a variety of databases provided by the.
FDA, for example, "Approved Oncology Drugs"
(http://www.fda.gov/cder/cancer/approved.htm), "Orange Book"
(http://www.fda.gov/cder/orange/default.htm), or from the information on the home pages provided by Pharmaceuticals and Medical Devices Agency of Japan (http://www.info.pmda.go.jp/). The information about the anticancer agents stored in these databases is incorporated by reference herein in the present invention.
For example, according to the home pages provided by Pharmaceuticals and Medical Devices Agency of Japan, the package insert of TAXOTERE injection (registered trade mark; trade name of docetaxel) describes the dosage and administration of docetaxel as follows: "1. breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer; dosage and administration for each indication; 1.
usually, intravenously injected by infusion at a dose of 60 mg/m2 as docetaxel for an adult over 1 hour once a day at intervals of 3 - 4 weeks. The dosage may be increased or decreased depending on the condition, but the highest dose is up to 70 mg/m2 at a time." And the package insert of RITUXAN Injection (registered trade mark;
trade name of rituximab) describes as follows: "the dosage and administration:
CD20-positive B-cell non-Hodgkin's lymphoma ; dosage and administration 1. the recommended dosage for an adult of rituximab (genetical recombination) (JAN) is 375 mg/m2 per one dose, given as an IV infusion once weekly. The maximum administering frequency is assumed to be eight times."
[0015] The following is partially extracted Dosage and Administration regarding each anticancer agent disclosed in "Approved Oncology Drugs". For practical administration, it will be appreciated naturally that the complete information has to be taken into consideration.
Docetaxel : "Breast Cancer: The recommended dose of TAXOTERE is 60-100 mg/m2 administered intravenously over 1 hour every 3 weeks. Non Small Cell Lung Cancer: The recommended dose of TAXOTERE is 75 mg/m2 administered intravenously over 1 hour every 3 weeks."
Carboplatin : "Single agent therapy: PARAPLATIN (trade name of carboplatin), as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks."
Cisplatin : "Advanced Bladder Cancer: PLATINOL-AQ (trade name of cisplatin injection) should be administered as a single agent at a dose of 50-70 mg/m2 I.V. per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy."
Paclitaxel : "In patients previously treated with chemotherapy for ovarian cancer, the recommended regimen is TAXOL(trade name of paclitaxel) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks. For patients with carcinoma of the breast, TAXOL at a dose of 175 mg/m2 administered intravenously over 3 hours every 3 weeks has been shown to be effective after failure of chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy."
Vinorelbine : "The usual initial dose of NAVELBINE (trade name of vinorelbine) is 30 mg/mz administered weekly. The recommended method of administration is an intravenous injection over 6 to 10 minutes."
[0016] Gemcitabine : "GEMZAR (trade name of gemcitabine) is for intravenous use only. Adults Single-Agent Use : Pancreatic Cancer -should be administered by intravenous infusion at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks."
Irinotecan : "Starting Dose and Dose Modifications Weekly Dosage Schedule: The usual recommended starting dose of CAMPTOSAR Injection (trade name of Irinotecan injection) is 125 mg/m2. In patients with a combined history of prior pelvic/abdominal irradiation and modestly elevated serum total bilirubin levels (1.0 to 2.0 mg/dL) prior to treatment with CAMPTOSAR, there may be a substantially increased likelihood of grade 3 or 4 neutropenia. All doses should be administered as an intravenous infusion over 90 minutes. The recommended treatment regimen (one treatment course) is once weekly treatment for 4 weeks, followed by a 2-week rest period."
[0017] Doxorubicin : "Ovarian Cancer Patients Doxil (trade name of doxorubicin HCl liposome injection) should be administered intravenously at a dose of 50 mg/m2 (doxorubicin HCl equivalent) at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related AEs are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every 4 weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. A minimum of 4 courses is recommended because median time to response in clinical trials was months."
Dacarbazine ="Malignant Melanoma: The recommended dosage is 2 to 4.5mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. 2 An alternate recommended dosage is 250mg/square meter body surface/day I.V. for 5 days.
Treatment may be repeated every 3 weeks. "
Rituximab : The recommended dosage of RITUXAN (trade name of rituximab) is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
Ifosfamide : IFEX (trade name of ifosfamide) should be administered intravenously at a dose of 1.2 g/m2 per day for 5 consecutive days.
Etoposide : In small cell lung cancer, the VePesid For Injection dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.
Cytarabine : In the induction therapy of acute non-lymphocytic leukemia, the usual cytarabine dose in combination with other anticancer drugs is 100 mg/m2/day by continuous IV infusion (days 1 to 7) or 100 mg/m2 IV every 12 hours (days 1 to 7).
Regarding R-ICE and R-DHAP, detailed information is available from references on clinical trials as follows:
[0018] R-ICE (Blood. 2006 May 15; 103(10):3684-8): Rituximab (375 mg/m2) is administered on day 1 of each cycle and 48 hours before the initiation of the first cycle of ICE. ICE chemotherapy is administered on an inpatient basis beginning on day 3 of each cycle. Etoposide (100 mg/m2) is administered as an intravenous bolus daily for 3 days, from days 3 to 5. Carboplatin capped at 800 mg is administered as a bolus infusion on day 4. Ifosfamide (5000 mg/mz), mixed with an equal amount of mesna, was administered as a continuous intravenous infusion over 24 hours beginning on day 4.
R-DHAP (Blood. 1988 Jan ;71=117-22, Leukemia & Lymphoma 2007 May;48(5):897-904): Rituximab (375 mg/m2) is administered on day 1 of each cycle and 48 hours before the initiation of the first cycle of DHAP. Cisplatin (100 mg) is administered as a continuous intravenous infusion over 24 hours beginning on day 1.
Cytarabine (2000 mg/m2) is administered as an intravenous bolus twice daily on day 2.
Additionally, in order to control chemotherapy-induced nausea and vomiting, dexamethasone (40 mg/m2) is administered as an intravenous bolus daily for 3 days, from days 1 to 4.
[0019] In using the combined therapy of the present invention, the same dose as that usually given as a single agent or a slightly reduced dose (for example, 0.10 -0.99 times the highest dose as a single agent) may be given through a normal administration route. In the case of an anticancer agent which is administered in a certain administration cycle, the cycle may properly be adjusted so as to be suitable for combination use with YM155. Specifically, the frequency of administration, dosage, time of infusion, medication cycle, and the like may be determined properly according to individual cases considering the state of patients, age, gender, etc.
The mode of medication in combinational administration of YM155 and an anticancer agent is not particularly limited as long as a suitable administration route, frequency of administration and dosage are properly selected. For example, (1) administration of a composition containing YM155 and an anticancer agent, i.e., as a single preparation; (2) combinational administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through the same administration route; (3) time interval difference administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through the same administration route (for example, YM155 is administered first, and then an anticancer agent, or vice versa); (4) combinational administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through different administration routes; and (5) time interval difference administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through different administration routes (for example, YM155 is administered first, and then an anticancer agent, or vice versa).
In a preferred embodiment of combinational administration of the present invention, YM155 and another anticancer agent are separately formulated, and the resulting 2 types of preparations are administered concomitantly (including partially concomitant) or at a time interval through an administration route suitable to each preparation and in a proper frequency of administration. In the time interval difference administration, it is necessary to administer the preparations at a time interval which satisfies the potentiation of the anticancer effect.
Preferably, the 2nd preparation is administered within 2 weeks, more preferably 7 days, yet more preferably 3 days, after administration of the first preparation. When there is concern about a drug-drug interaction between YM155 and another anticancer agent, it is appropriate to administer them at an interval required for avoidance of such an interaction.
[0020] As shown in Test Examples, it was found that the therapeutic effect on cancer was potentiated by combined therapy of YM155 and an existing anticancer agent., The effect was confirmed by significant reduction of the tumor volume in comparison with that by the respective single application of YM155 or an existing anticancer agent. On the other hand, the body weight was equal to that at the administration of an existing anticancer agent as a single agent, indicating that possibly there is no change in adverse reaction in the combination use.
Therefore, it was found that the combination use of YM155 and an existing anticancer agent potentiates an anticancer action with no change of adverse reaction, resulting in a satisfactory therapeutic effect for cancer.
Surprisingly, it was elucidated that a combination use of YM155 and a taxane-type anticancer agent, particularly docetaxel, exhibited a much better cancer-regression action. In an animal model as shown in the Test Examples, an anticancer effect was confirmed which was so potent that disappearance of cancer was attained. In a combination use with docetaxel, disappearance of cancer was observed in all or part of the animals tested, and totally the tumor volume was reduced to almost 0 (zero) after the lapse of 35 days; no tendency was observed toward the growth of cancer cells again. From this finding, it was estimated that the inhibitory effect of YM155 on expression of survivin and the anticancer effect of docetaxel worked synergistically to attain a particularly excellent therapeutic effect for cancer.
[0021] In a preliminary test using an animal model to which an other type of cancer was transplanted, e.g., prostate cancer (PC-3), a taxane-type anticancer agent, docetaxel or paclitaxel, was administered combined with YM155. As a result, the anticancer action was potentiated in comparison with administration of the respective single agents and the tumor volume was reduced well. This suggests that the combination use of YM155 potentiates the anticancer action of existing anticancer agents and induces a good cancer therapeutic effect not limited by kinds of cancers.
In addition, it has been disclosed in the above-cited references No. 14 to 17 that YM155 perse exhibits a potent anticancer action on a variety of cancers in which survivin is involved. These findings show that the method of the invention for treatment of cancers by co-administration of YM155 and an existing anticancer agent, in which the inhibitory effect of YM155 on expression of survivin and the anticancer effect of the existing anticancer agent work synergistically, affords a high therapeutic effect for cancers and can be applied to treatment of a variety of cancers. In particular, since YM155 has a new mechanism of action working to inhibit the expression of survivin, it is useful in the treatment of kinds of cancers which are resistant to existing anticancer agents.
[0022] The anticancer agents used in combination with YM155 include, preferably, those usually used against an objective kind of cancers, particularly those used in a standard therapy. For example, docetaxel for hormone-resistant prostate cancer, dacarbazine for melanoma, one or more agents selected from docetaxel, paclitaxel, carboplatin, cisplatin and gemcitabine for lung cancer, or R-ICE
and R-DHAP for lymphoma, are included. The combination use of YM155 in addition to these anticancer agents used in a standard therapy, is expected to potentiate the therapeutic effect for cancers in the objective kind of cancers.
EXAMPLES
DISCLOSURE OF THE INVENTION
Problems that the Invention is to Solve [0006] When the combinational drugs are used together, there are a lot of cases where the side effects increase as well as the anti-tumor effects.
Therefore there are many difficulties in combining two or more anti-tumor agents.
Especially, a combination of anticancer agents with a synergistic anticancer action resulting in marked reduction of cancer cells and further complete removal of the cancer cells, leading to a complete cure of cancer without an increase of side effects, is eagerly desired.
Means for Solving the Problems [0007] The present inventors have found that a combination use of 1-(2 -methoxyethyl)-2 -methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-lH-naph tho[2,3-d]imidazol-3-ium bromide (YM155) with an existing anticancer agent or agents, particularly, docetaxel or rituximab, unexpectedly potentiates the anticancer effect. Thus, the present invention was completed.
That is, the present invention relates to a pharmaceutical composition comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient, for treating cancer in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin (CBDCA), cisplatin (CDDP), paclitaxel (TXL), vinorelbine (VIN), gemcitabine (GEM), irinotecan (CPT-11), docetaxel (TXT), doxorubicin (DXR), dacarbazine (DTIC) and rituximab(RTX), or ii) a rituximab-containing combination therapy selected from R-ICE (consisting of rituximab, ifosfamide (IFM), carboplatin and etoposide (ETP)), and R-DHAP
(consisting of rituximab, cytarabine (ara-C) and cisplatin as anticancer, agents).
Usually, R-DHAP contains dexamethasone as an agent for treatment of chemotherapy-induced nausea and vomiting in addition to the above-mentioned anti-cancer drugs.
[0008] In the invention, the preferable compositions are as follows:
(1) The composition as described above, wherein the combined therapy comprises the use of docetaxel or paclitaxel.
(2) The composition as described in (1), wherein the combined therapy comprises the use of docetaxel.
(3) The composition as described in (2), wherein the composition is for treating hormone-resistant prostate cancer.
(4) The composition as described above, wherein the composition is for treating lung cancer and the combined therapy comprises the use of one or more agents selected from docetaxel, paclitaxel, carboplatin, cisplatin and gemcitabine.
(5) The composition as described above, wherein the combined therapy comprises the use of rituximab.
(6) The composition as described above, wherein the combined therapy comprises the use of a combination therapy selected from R-ICE and R-DHAP.
(7) The composition as described in (6), wherein the combined therapy comprises the use of a combination therapy R-ICE.
(8) The composition as described in (5) or (6), wherein the composition is for treating lymphoma.
(9) The composition as described above, wherein the composition is a formulation for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-nap htho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 1 -mg/m2/day continuously for a period of 4 - 14 days.
(10) A composition as described in (9), wherein the formulation is for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl) -4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 3 - 8 mg/m2/day continuously for 7 days, followed by drug holidays of 14 days, which administration cycle as one cycle is repeated depending on the conditions.
[0009] The present invention also relates to the following inventions:
(11) Use of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl) -4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide for production of a medicament for treating cancer, wherein the medicament is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP.
(12) An agent for cancer treatment comprising as an active ingredient 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide, wherein the agent is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP.
(13) A potentiator of an anticancer effect of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE and R-DHAP, wherein the potentiator comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-naphtho[2,3-d]imidazol-3-ium bromide as an active ingredient.
(14) A kit comprising at least one cycle dosage of 1-(2-methoxyethyl)-2 -methyl-4,9-dioxo-3-(pyrazin-2 -ylmethyl)-4,9-dihydro-lH-nap htho[2,3-d]imidazol-3-ium bromide and i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) anticancer agents for a combination therapy selected from R-ICE and R-DHAP.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 contains graphs showing the results of Test Examples 1 and 2 in which YM155 was administered in combination with docetaxel. (a) -(c) are graphs respectively showing the tumor volume (mm3) in Test Example 1, Test Example 2B) and Test Example 2A); (d) - (f) are graphs respectively showing body weight (g) in Test Example 1, Test Example 2B) and Test Example 2A).
Figure 2, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and carboplatin (CBDCA) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and cisplatin (CDDP) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 3, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and gemicitabine (GEM) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and vinorelbine (VIN) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 4, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and doxorubicin (DXR) in Test Example 3, and (b) shows the mean body weight (g), respectively. (c) shows the mean tumor volume (mm3) from co-administration of YM155 and irinotecan (CPT-11) in Test Example 3, and (d) shows the mean body weight (g), respectively.
Figure 5, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and paclitaxel (TXL) in Test Example 3, and (b) shows the mean body weight (g), respectively.
Figure 6, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and Dacarbazine (DTIC) in Test Example 4, and (b) shows the mean body weight (g), respectively.
Figure 7, (a) shows the mean tumor volume (mm3) from co-administration of YM155 and R-ICE (RICE) in Test Example 5, and (b) shows the mean body weight (g), respectively. And (c) shows the mean tumor volume (mm3) from co-administration of YM155 and Rituximab (RTX) in Test Example 5, and (d) shows the mean body weight (g), respectively.
BEST MODE FOR CARRYING OUT OF THE INVENTION
[0011] The following describes the invention in detail.
YM155 used in the invention is readily available according to the processes of production as disclosed in International Publication 01/60803 and International Publication 2004/092160.
YM155 may be administered orally or parenterally, and preferably intravenously. In this connection, the injection preparation for intravenous administration includes those containing sterile aqueous or non-aqueous solutions, suspensions, and emulsions. The aqueous solvent includes, for example, distilled water for injection and physiological saline. The non-aqueous solvent includes, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, polysorbate 80 (trade name), and the like. Such compositions may contain further tonicity adjusting agents, antiseptics, moistening agents, emulsifying agents, dispersing agents, stabilizers, and solubilizing agents.
These may be sterilized, for example, by filtration through a bacterial filter, blending of sterilizers or irradiation. Alternatively, it is possible to prepare a germ-free solid composition and dissolve or suspend it in sterile water or a sterile solvent for injection immediately before use.
[0012] In intravenous administration, YM155 may be administered usually at 0.1 - 20 mg/m2/day, preferably at 1- 10 mg/m2/day, once a day or divided in plural doses, or continuously by infusion (continuous instillation).
Preferably, it may be infused at 3 - 10 mg/m2/day continuously for a period of 4 days to 20 days, more preferably 4 days to 14 days, or 5 days, 7 days, 10 days or 14 days, and yet more preferably infused continuously for 7 days. When the administration is further continued, it is preferable to employ a medication cycle comprising a term of drug holidays of 1 day to 2 months, preferably 7 days to 21 days, more preferably 14 days, after termination of the above term of medication. In a particularly preferred embodiment, it may be administered continuously by infusion at a dose of 3 - 8 mg/m2/day for 7days, followed by drug holidays of 14 days; this cycle as one cycle is repeated depending on the conditions. When an anticancer agent used in combination has a particular medication cycle, it is preferable to establish a medication cycle for YM155 and said anticancer agent so that potentiation is attained. Specifically, the frequency of administration, dosage, time of infusion, medication cycle, and the like, may be determined properly according to individual cases considering the kind of anticancer agent, state of the patients, age, gender, etc.
[0013] The following table lists existing anticancer agents suitable for combination use with YM155 of the invention, together with the main indications of cancer. The cancers indicated for these anticancer agents in the combined therapy of the invention is not limited to these cancers.
[Table 1) Anticancer Agent Main Indications of Cancer Carboplatin CBDCA colon cancer, lung cancer Cisplatin CDDP colon cancer, lung cancer Paclitaxel TXL lung cancer, ovary cancer Vinorelbine VNR lung cancer Gemcitabine GEM lung cancer, pancreas cancer, colon cancer Irinotecan CPT- 11 colon cancer Docetaxel TXT prostate cancer, lung cancer Doxorubicin DXR bladder cancer Dacarbazine DTIC malignant melanoma Rituximab RTX CD20-positive B-cell non-Hodgkin's lymphoma Third line chemotherapy of germ cell testicular Ifosfamide IFM cancer when used in combination with certain other approved antineoplastic agents In combination with other approved Etoposide ETP chemotherapeutic agents as first line treatment in patients with small cell lung cancer.
Cytarabine ara-C Leukemia [0014] The above-mentioned anticancer agents have already been used clinically, and their administration route, administration cycle, and dose are apparent for a person skilled in the art. The appropriate dosage and administration are different depending on the species of cancer, condition and combinational agents.
Detailed information is available from a variety of databases provided by the.
FDA, for example, "Approved Oncology Drugs"
(http://www.fda.gov/cder/cancer/approved.htm), "Orange Book"
(http://www.fda.gov/cder/orange/default.htm), or from the information on the home pages provided by Pharmaceuticals and Medical Devices Agency of Japan (http://www.info.pmda.go.jp/). The information about the anticancer agents stored in these databases is incorporated by reference herein in the present invention.
For example, according to the home pages provided by Pharmaceuticals and Medical Devices Agency of Japan, the package insert of TAXOTERE injection (registered trade mark; trade name of docetaxel) describes the dosage and administration of docetaxel as follows: "1. breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer; dosage and administration for each indication; 1.
usually, intravenously injected by infusion at a dose of 60 mg/m2 as docetaxel for an adult over 1 hour once a day at intervals of 3 - 4 weeks. The dosage may be increased or decreased depending on the condition, but the highest dose is up to 70 mg/m2 at a time." And the package insert of RITUXAN Injection (registered trade mark;
trade name of rituximab) describes as follows: "the dosage and administration:
CD20-positive B-cell non-Hodgkin's lymphoma ; dosage and administration 1. the recommended dosage for an adult of rituximab (genetical recombination) (JAN) is 375 mg/m2 per one dose, given as an IV infusion once weekly. The maximum administering frequency is assumed to be eight times."
[0015] The following is partially extracted Dosage and Administration regarding each anticancer agent disclosed in "Approved Oncology Drugs". For practical administration, it will be appreciated naturally that the complete information has to be taken into consideration.
Docetaxel : "Breast Cancer: The recommended dose of TAXOTERE is 60-100 mg/m2 administered intravenously over 1 hour every 3 weeks. Non Small Cell Lung Cancer: The recommended dose of TAXOTERE is 75 mg/m2 administered intravenously over 1 hour every 3 weeks."
Carboplatin : "Single agent therapy: PARAPLATIN (trade name of carboplatin), as a single agent, has been shown to be effective in patients with recurrent ovarian carcinoma at a dosage of 360 mg/m2 I.V. on day 1 every 4 weeks."
Cisplatin : "Advanced Bladder Cancer: PLATINOL-AQ (trade name of cisplatin injection) should be administered as a single agent at a dose of 50-70 mg/m2 I.V. per cycle once every 3 to 4 weeks depending on the extent of prior exposure to radiation therapy and/or prior chemotherapy."
Paclitaxel : "In patients previously treated with chemotherapy for ovarian cancer, the recommended regimen is TAXOL(trade name of paclitaxel) 135 mg/m2 or 175 mg/m2 administered intravenously over 3 hours every 3 weeks. For patients with carcinoma of the breast, TAXOL at a dose of 175 mg/m2 administered intravenously over 3 hours every 3 weeks has been shown to be effective after failure of chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy."
Vinorelbine : "The usual initial dose of NAVELBINE (trade name of vinorelbine) is 30 mg/mz administered weekly. The recommended method of administration is an intravenous injection over 6 to 10 minutes."
[0016] Gemcitabine : "GEMZAR (trade name of gemcitabine) is for intravenous use only. Adults Single-Agent Use : Pancreatic Cancer -should be administered by intravenous infusion at a dose of 1000 mg/m2 over 30 minutes once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles should consist of infusions once weekly for 3 consecutive weeks out of every 4 weeks."
Irinotecan : "Starting Dose and Dose Modifications Weekly Dosage Schedule: The usual recommended starting dose of CAMPTOSAR Injection (trade name of Irinotecan injection) is 125 mg/m2. In patients with a combined history of prior pelvic/abdominal irradiation and modestly elevated serum total bilirubin levels (1.0 to 2.0 mg/dL) prior to treatment with CAMPTOSAR, there may be a substantially increased likelihood of grade 3 or 4 neutropenia. All doses should be administered as an intravenous infusion over 90 minutes. The recommended treatment regimen (one treatment course) is once weekly treatment for 4 weeks, followed by a 2-week rest period."
[0017] Doxorubicin : "Ovarian Cancer Patients Doxil (trade name of doxorubicin HCl liposome injection) should be administered intravenously at a dose of 50 mg/m2 (doxorubicin HCl equivalent) at an initial rate of 1 mg/min to minimize the risk of infusion reactions. If no infusion-related AEs are observed, the rate of infusion can be increased to complete administration of the drug over one hour. The patient should be dosed once every 4 weeks, for as long as the patient does not progress, shows no evidence of cardiotoxicity, and continues to tolerate treatment. A minimum of 4 courses is recommended because median time to response in clinical trials was months."
Dacarbazine ="Malignant Melanoma: The recommended dosage is 2 to 4.5mg/kg/day for 10 days. Treatment may be repeated at 4 week intervals. 2 An alternate recommended dosage is 250mg/square meter body surface/day I.V. for 5 days.
Treatment may be repeated every 3 weeks. "
Rituximab : The recommended dosage of RITUXAN (trade name of rituximab) is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
Ifosfamide : IFEX (trade name of ifosfamide) should be administered intravenously at a dose of 1.2 g/m2 per day for 5 consecutive days.
Etoposide : In small cell lung cancer, the VePesid For Injection dose in combination with other approved chemotherapeutic drugs ranges from 35 mg/m2/day for 4 days to 50 mg/m2/day for 5 days.
Cytarabine : In the induction therapy of acute non-lymphocytic leukemia, the usual cytarabine dose in combination with other anticancer drugs is 100 mg/m2/day by continuous IV infusion (days 1 to 7) or 100 mg/m2 IV every 12 hours (days 1 to 7).
Regarding R-ICE and R-DHAP, detailed information is available from references on clinical trials as follows:
[0018] R-ICE (Blood. 2006 May 15; 103(10):3684-8): Rituximab (375 mg/m2) is administered on day 1 of each cycle and 48 hours before the initiation of the first cycle of ICE. ICE chemotherapy is administered on an inpatient basis beginning on day 3 of each cycle. Etoposide (100 mg/m2) is administered as an intravenous bolus daily for 3 days, from days 3 to 5. Carboplatin capped at 800 mg is administered as a bolus infusion on day 4. Ifosfamide (5000 mg/mz), mixed with an equal amount of mesna, was administered as a continuous intravenous infusion over 24 hours beginning on day 4.
R-DHAP (Blood. 1988 Jan ;71=117-22, Leukemia & Lymphoma 2007 May;48(5):897-904): Rituximab (375 mg/m2) is administered on day 1 of each cycle and 48 hours before the initiation of the first cycle of DHAP. Cisplatin (100 mg) is administered as a continuous intravenous infusion over 24 hours beginning on day 1.
Cytarabine (2000 mg/m2) is administered as an intravenous bolus twice daily on day 2.
Additionally, in order to control chemotherapy-induced nausea and vomiting, dexamethasone (40 mg/m2) is administered as an intravenous bolus daily for 3 days, from days 1 to 4.
[0019] In using the combined therapy of the present invention, the same dose as that usually given as a single agent or a slightly reduced dose (for example, 0.10 -0.99 times the highest dose as a single agent) may be given through a normal administration route. In the case of an anticancer agent which is administered in a certain administration cycle, the cycle may properly be adjusted so as to be suitable for combination use with YM155. Specifically, the frequency of administration, dosage, time of infusion, medication cycle, and the like may be determined properly according to individual cases considering the state of patients, age, gender, etc.
The mode of medication in combinational administration of YM155 and an anticancer agent is not particularly limited as long as a suitable administration route, frequency of administration and dosage are properly selected. For example, (1) administration of a composition containing YM155 and an anticancer agent, i.e., as a single preparation; (2) combinational administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through the same administration route; (3) time interval difference administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through the same administration route (for example, YM155 is administered first, and then an anticancer agent, or vice versa); (4) combinational administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through different administration routes; and (5) time interval difference administration of 2 species of preparations separately prepared from YM155 and an anticancer agent, respectively, through different administration routes (for example, YM155 is administered first, and then an anticancer agent, or vice versa).
In a preferred embodiment of combinational administration of the present invention, YM155 and another anticancer agent are separately formulated, and the resulting 2 types of preparations are administered concomitantly (including partially concomitant) or at a time interval through an administration route suitable to each preparation and in a proper frequency of administration. In the time interval difference administration, it is necessary to administer the preparations at a time interval which satisfies the potentiation of the anticancer effect.
Preferably, the 2nd preparation is administered within 2 weeks, more preferably 7 days, yet more preferably 3 days, after administration of the first preparation. When there is concern about a drug-drug interaction between YM155 and another anticancer agent, it is appropriate to administer them at an interval required for avoidance of such an interaction.
[0020] As shown in Test Examples, it was found that the therapeutic effect on cancer was potentiated by combined therapy of YM155 and an existing anticancer agent., The effect was confirmed by significant reduction of the tumor volume in comparison with that by the respective single application of YM155 or an existing anticancer agent. On the other hand, the body weight was equal to that at the administration of an existing anticancer agent as a single agent, indicating that possibly there is no change in adverse reaction in the combination use.
Therefore, it was found that the combination use of YM155 and an existing anticancer agent potentiates an anticancer action with no change of adverse reaction, resulting in a satisfactory therapeutic effect for cancer.
Surprisingly, it was elucidated that a combination use of YM155 and a taxane-type anticancer agent, particularly docetaxel, exhibited a much better cancer-regression action. In an animal model as shown in the Test Examples, an anticancer effect was confirmed which was so potent that disappearance of cancer was attained. In a combination use with docetaxel, disappearance of cancer was observed in all or part of the animals tested, and totally the tumor volume was reduced to almost 0 (zero) after the lapse of 35 days; no tendency was observed toward the growth of cancer cells again. From this finding, it was estimated that the inhibitory effect of YM155 on expression of survivin and the anticancer effect of docetaxel worked synergistically to attain a particularly excellent therapeutic effect for cancer.
[0021] In a preliminary test using an animal model to which an other type of cancer was transplanted, e.g., prostate cancer (PC-3), a taxane-type anticancer agent, docetaxel or paclitaxel, was administered combined with YM155. As a result, the anticancer action was potentiated in comparison with administration of the respective single agents and the tumor volume was reduced well. This suggests that the combination use of YM155 potentiates the anticancer action of existing anticancer agents and induces a good cancer therapeutic effect not limited by kinds of cancers.
In addition, it has been disclosed in the above-cited references No. 14 to 17 that YM155 perse exhibits a potent anticancer action on a variety of cancers in which survivin is involved. These findings show that the method of the invention for treatment of cancers by co-administration of YM155 and an existing anticancer agent, in which the inhibitory effect of YM155 on expression of survivin and the anticancer effect of the existing anticancer agent work synergistically, affords a high therapeutic effect for cancers and can be applied to treatment of a variety of cancers. In particular, since YM155 has a new mechanism of action working to inhibit the expression of survivin, it is useful in the treatment of kinds of cancers which are resistant to existing anticancer agents.
[0022] The anticancer agents used in combination with YM155 include, preferably, those usually used against an objective kind of cancers, particularly those used in a standard therapy. For example, docetaxel for hormone-resistant prostate cancer, dacarbazine for melanoma, one or more agents selected from docetaxel, paclitaxel, carboplatin, cisplatin and gemcitabine for lung cancer, or R-ICE
and R-DHAP for lymphoma, are included. The combination use of YM155 in addition to these anticancer agents used in a standard therapy, is expected to potentiate the therapeutic effect for cancers in the objective kind of cancers.
EXAMPLES
[0023] The followings show the results of pharmacological tests indicating the usefulness of the combination use of the invention.
Test Example 1:
1) Test Compounds The dose levels are expressed in terms of YM155, the cationic moiety of the drug substance. Docetaxel hydrate (Taxotere INJECTION) was purchased from Sanofi-Aventis Pharma Ltd. (West Lavel, FRA) and used as docetaxel.
2) Preparation of Test Compounds YM155 was dissolved in and diluted with physiological saline in order to prepare dosing solutions (concentrations calculated using the following formulation: dose x mean body weight for each group / daily release volume).
These solutions were prepared immediately before the implantation of an osmotic pump (Alzet model 1007D Micro-Osmotic Pump, DURECT Co., CA, USA) into the test subjects. The solutions were then loaded into the pump. Docetaxel was diluted with physiological saline to prepare 2mg/mL solutions immediately before administration.
3) Cells The human lung carcinoma cell line Calu 6 (HTB-56, Lot No. 208280) was obtained from American Type Culture Collection (VA, USA). The cells were cultured at 37 C in a 5% CO2 atmosphere in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum. The cells were collected with trypsin, suspended in PBS at 6x 107cells/mL, and then mixed with an equivalent volume of Matrigel Basement Membrane Matrix (Becton Dickinson Co., Bedford, MA, USA).
[00241 4) Animals Five-week-old male nude mice (CAnN.Cg-Foxnlnu/CrlCrlj(nu/nu)) were purchased from Charles River Laboratories Japan, Inc (Kanagawa, Japan). They were maintained on a standard diet and water throughout the experiments under specific pathogen-free conditions. The cells were cultured in vitro and 3 x106 cells/0.1 mL/mouse were grafted subcutaneously into the flank of 6-week-old nude mice.
The mice with tumor volumes (lengthxwidth2x0.5) of 97.3 to 182.7 mm3 were divided into groups. This was done using SAS software in order to min;m;ze intragroup and intergroup tumor volume variation.
5) Administration and Measurement The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2 mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxel 20 mg/kg/day (iv bolus on day 0, 4, and 8) Combination group YM155 2 mg/kg/day + Docetaxe120 mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 0, and iv bolus injection of physiological saline on days 0, 4 and 8. The YM155 group received a 7-day sc continuous infusion of YM155 at 2 mg/kg/day starting on day 0, and iv bolus injection of physiological saline on days 0, 4 and 8. The docetaxel group received iv bolus injection of docetaxel at 20 mg/10 mL/kg on days 0, 4 and 8, as well as a 7-day sc continuous infusion of physiological saline starting on day 0. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
Body weight and tumor diameter were measured every 3-4 days using calipers, and tumor volume was determined by calculating the volume of an ellipsoid using the formula: lengthxwidth2x0.5. Antitumor activities are expressed as percent inhibition of tumor growth (% inh) and percent regression of the tumor (% reg). The percent inhibition of tumor growth on day 35 was calculated for each group using the following formula: 100 x[1-{(mean tumor volume of each group on day 35) - (mean tumor volume of each group on day 0)} /{(mean tumor volume of the control group on day 35) - (mean tumor volume of the control group on day 0)}]. The percent regression of the tumor was calculated for all groups with observed tumor regression, using the following formula: 100 x{1-(mean tumor volume of each group on day 35) / (mean tumor volume of each group on day 0)}. The number of Complete Regressions (CRs) in all groups were checked during the experimental period. The CR is defined by instances in which the tumor burden falls bellow the limit of palpation.
[0025] 6) Statistical Analysis Values are expressed as the mean the standard error of the mean (SEM).
Tumor volume and body weight on day 35 were compared between each single compound group and combination group using the Student's t-test. P values of less than 5% are considered significant. SAS software was used for data processing.
7) RESULTS
YM155 was administered concomitantly with docetaxel, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day and docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression in all cases on day 35 (Table 2 and Figure 1-(a)). YM155 treatment alone inhibited tumor growth by 99% on day 35. Docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 52% on day 35. During the weeks of observation, YM155 or docetaxel treatment group showed tumor regression during the first two weeks which was followed by successive tumor regrowth during the last few weeks. On the other hand, YM155 in combination with docetaxel showed complete regression of the tumors in all cases. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(d)).
[0026] [Table 21 Tumor Volume (mm3) Body Weight (g) Antitumor Activity Number of Treatment Groups Complete day 0 day 35 day 35 (% inh l% reg) Regressions Vehicle Control 120.9 7.0 2848.0 185.1 26.56 0.56 --- 0/8 YM155 121.4 6.9 142.3 16.9 26.13 0.56 99% 0/8 Docetaxel 121.4 7.0 58.0 20.4 24.95 0.54 >100% / 52% 0/8 YM155 + Docetaxel 121.1 7.2 0.0 0.0 '="~ 24.11 0.66 "=NS >100% / 100% 8/8 Values are expressed as the mean SEM (n=8). *: P<0.05, a significant difference of the combination group versus Docetaxel group. ##: F<0.01 and #:
P<0.05, significant. differences of the combination group versus YM155 group.
N.S.: no significance from Docetaxel group (Student's t-test).
8) DISCUSSION
Results of this study indicate that YM155 significantly potentiate the anti-tumor activity of docetaxel without an increase in systemic toxicity, which is evidenced by overt symptoms such as body weight loss. The results also suggest that YM155 in combination with docetaxel is tolerated by mice, and that makes a strong combination for the treatment of cancer.
[0027] Test Example 2 The following study was conducted in the same way as Test Example 1 except for the administration timing.
A) The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxe120mg/kg/day (iv bolus on day 7, 11, and 15) Combination group YM155 2mg/kg/day - Docetaxe120mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 0, and iv bolus injection of physiological saline on days 7, lland 15. The YM155 group received a 7-day sc continuous infusion of YM155 at 2mg/kg/day starting on day 0 and iv bolus injection of physiological saline on days 7, 11 and 15. The docetaxel group received iv bolus injection of docetaxel at 20mg/lOmL/kg on days 7, 11 and 15, as well as a 7-day sc continuous infusion of physiological saline starting on day 0. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
RESULTS
Docetaxel was administered following the administration of YM155, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day with docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression by 99% on day 35 (Table 3 and Figure 1-(c)). YM155 treatment alone inhibited tumor growth by 99% on day 35. docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 10% on day 35. During the 5 weeks of observation, YM155 or docetaxel group showed tumor regression during the first two weeks which was followed by successive tumor regrowth during the last few weeks. On the other hand, the combination group of YM155 with docetaxel showed tumor regression in all cases and complete regression of the tumors in 7 cases of 8 cases, and anticancer effect was significantly (P<0.01) potentiated as compared to each single compound treatment group. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(f)).
,[0028] [Table 31 Titmor Volume (mm3) Body Weight (g) Antitumor Activity Treatment Groups Number of CRs day 0 day 35 day 35 (% inh l% reg ) Vehicle Control 208.5 18.6 4237.0 545.7 25.88 0.70 --- 0/8 YM155 208.5 18.6 251.8 50.7 26.25 0.25 99% /- 0/8 Docetaxel 209.1 18.3 188.8 29.1 21.03 0.94 >100%/ 10% 0/8 YM155-+Docetaxel 208.6 18.1 1.3 1.3 "=* 24.13 0.78'=* >100%/ 99% 7/8 Values are expressed as the mean SEM (n=8). **: F<0.01 and P<0.05, significant differences of the combination group versus Docetaxel group. #:
P<0.05, significant differences of the combination group versus YM155 group.
(Student's t-test).
[0029] B) The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxe120mg/kg/day (iv bolus on day 0, 4, and 8) Combination group Docetaxe120mg/kg/day - YM155 2mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 8, and iv bolus injection of physiological saline on days 0, 4 and 8. The YM155 group received a 7-day sc continuous infusion of YM155 at 2 mg/kg/day starting on day 8, and iv bolus injection of physiological saline on days 0, 4 and 8. The docetaxel group received iv bolus injection of docetaxel at 20 mg/10 mL/kg on days 0, 4 and 8, as well as a 7-day sc continuous infusion of physiological saline starting on day 8. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
RESULTS
YM155 was administered following the administration of Docetaxel, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day with docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression by 97% on day 35 (Table 4 and Figure 1-(b)). YM155 treatment alone inhibited tumor growth by 61% on day 35. Docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 68%
on day 35. During the 5 weeks of observation, YM155 or docetaxel treatment group showed tumor regrowth during the last few weeks. On the other hand, YM155 in combination with docetaxel showed complete regression of the tumors in three cases, and anticancer effect was significantly (P<0.01) potentiated as compared to each single compound treatment group on day 35. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(e)).
[0030] [Table 4]
Tumor Volume (mm3) Body Weight (g) Antitumor Activity Treatment Groups Number of CRs day 0 day 35 day 35 (% inh l% reg) Vehicle Control 207.7 23.5 3380.8 325.4 24.33 0.85 --- 0/8 YM155 206.9 21.8 1437.5 225.5 24.80 1.01 61 %/- 0/8 Docetaxel 210.0 22.6 67.2 15.1 23.84 1.01 >100%/ 68% 0/8 Docetaxel -YM155 210.1 20.4 5.5 1.7 ","" 25.74 1.13 -1- >100% / 97% 3/8 Values are expressed as the mean SEM (n=8). **: F<0.01, a significant difference of the combination group versus Docetaxel group. ##: .F<0.01, a significant difference of the combination group versus YM155 group. N.S.: no significance from Docetaxel group (Student's ftest).
[0031] Test Example 3 The study was conducted in the same way as Test Example 1, except that the listed agents in Table 5 were used instead of Docetaxel according to the following dosage regimen.
[Table 5) Anticancer Agent Dosage Regimen Result Carboplatin CBDCA 60 mg/kg/day i.v. (day 0, 1) Fig. 2-(a) & (b) Cisplatin CDDP 3 mg/kg/day i.v. (day 0-4, 7-11) Fig. 2-(c) & (d) Gemcitabine GEM 200 mg/kg/day i.v. (day 0,3,6) Fig. 3-(a) & (b) Vinorelbine VNR 10 mg/kg/day i.v. (day 0, 7) Fig. 3-(c) & (d) Doxorubicin DXR 10 mg/kg/day i.v. (day 0, 7) Fig. 4-(a) & (b) Irinotecan CPT- 11 60 mg/kg/day i.v. (day 0-4) Fig. 4-(c) & (d) Paclitaxel TXL 10-15 mg/kg/day i.v. (day 0-4) Fig. 5-(a) & (b) (In the Table 5, i.v. means intravenous administration, for example, (day 0, 1) means once-a-day administration at the initial day of administration (day 0) and at the Ist day (day 1); (day 0-4) means once-a-day administration from the initial day of administration (day 0) to the 4th day (day 4), respectively.) Results were shown in Figure 2 to 5. In the figures, values are expressed as the mean f SEM (n=8). * P<0.05 versus the anticancer agent group, ##:
P<0.01 versus YM155 group, #: P<0.05 versus YM155 group, N.S.: no significance from YM155 group and the anticancer agent group respectively (Student's iftest).
The respective anticancer agents were purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
(0032] Test Example 4 The study was conducted in the same way as Test Example 1, except that Dacarbazine was used instead of Docetaxel and Melanoma A375 cells were used instead of Calu 6 cells according to the following dosage regimen (n=8).
Results were shown in Figure 6.
YM155 group YM155 3 mg/kg/day (7-day sc continuous infusion) Dacarbazine (DTIC) group Dacarbazine 200 mg/kg/day, i.v.(day0-5) Combination group YM155 3 mg/kg/day (7-day sc continuous infusion) +
Dacarbazine 200 mg/kg, i.v.(day0-5) Dacarbazine was purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
[0033] Test Example 5 The study was conducted in the same way as Test Example 1, except that a combination therapy R-ICE(RICE) or Rituximab(RTX) was used instead of Docetaxel, and lymphoma WSU-DLCL-2 cells were used instead of Calu 6 cells according to the following dosage regimen.
YM155 group YM155 1 mg/kg/day (7-day sc continuous infusion) RICE group RTX 50 mg/kg, i.v. (day 0) + (IFM 200 mg/kg+ETP 10 mg/kg), i.v. (day 1,2 and 3) + CBDCA 30 mg/kg, i.v. (day 1) YM155+RICE group YM155 1 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v. (day 0) + (IFM 200 mg/kg + ETP 10 mg/kg), i.v. (day 1,2 and 3) + CBDCA 30 mg/kg, i.v (day 1).
YM155+RTX group YM155 1 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v.(day 0).
Rituximab(RTX), carboplatin(CBDCA), ifosfamide (IFM), and etoposide (ETP) were purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
Results were shown in Figure 7. In the figures, values are expressed as the mean f SEM (n=6). **: P<0.01 versus RICE or RTX group, *: P'<0.05 versus RICE or RTX group, ##: P<0.01 versus YM155 group, N.S.: no significance from YM155 group and RICE or RTX group respectively (Student's t-test).
YM155 in combination with RICE showed complete regression of the tumors in one case, and YM155 in combination with RTX showed complete regression of the tumors in two cases.
The preliminary study was done by using the method similar to the above-mentioned YM155+RICE group, but a combination therapy R-DHAP was used instead of a combination therapy R-ICE, wherein R-DHAP was consisting of rituximab (50mg/kg i.v., day 0 and 2), cisplatin (5mg/kg, i.v., day 2), cytarabin (70mg/kg, i.v., day 4). The tumor volume was significantly (P<0.01) reduced in the combination group as compared to R-DHAP group on day 18.
[0034] Test Example 6 The study was conducted in the same way as Test Example 5 according to the following dosage regimen.
YM155 group: YM155 2 mg/kg/day (7-day sc continuous infusion) RICE group : RTX 50 mg/kg, i.v. (day 6 and 8) + (IFM 400 mg/kg +
CBDCA 30 mg/kg), i.v (day 9) + ETP 10 mg/kg, i.v (day 8, 9 and 1.0) YM155+RICE group YIVM155 2 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v. (day 6 and 8) + (IFM 400 mg/kg + CBDCA 30 mg/kg), i.v. (day 9) + ETP 10 mg/kg, i.v. (day 8, 9 and 10) Results were shown in table 6. In the table, values are expressed as the mean SEM (n=8, RICE group : n=6). **: P<0.01 versus RICE group, ##: F<0.01 versus YM155 group, N.S.: no significance from RICE group (Student's t-test).
YM155 in combination with RICE showed complete regression of the tumors in 6 cases of 8 cases.
[0035] (Table 61 Treatment Groups Tumor Volume (mm3) Body Weight (g) Antitumor Activity Number of day 0 day 28 day 28 (% inh l% reg) CRs Vehicle Control 404.4 14.5 2131.5 276.6 29.02 0.38 --- 0/8 YM155 405.1 13.8 1181.3 174.7 28.81 0.23 45% 0/8 RICE 404.2 13.0 1356.0 371.7 29.54 0.51 56% 0/6 YM155 ---> RICE 404.7 12.6 17.6 11.5 **= ## 28.55 0.26N.s. >100% / 96%
INDUSTRIAL APPLICABILITY
[00361 The pharmaceutical composition comprising YM155 as an active ingredient for treatment of a cancer in a combined therapy with one or more existing anticancer agents, in which the inhibitory action of YM155 on expression of survivin works synergistically with the anticancer effect of the existing anticancer agent, affords a high therapeutic effect for cancers and is useful in treatment of a variety of cancers to which existing anticancer agents are applied, accordingly. Thus, the pharmaceutical composition of the invention is useful in treatment of cancers, preferably all solid cancers and lymphomas, particularly skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and the like. Particularly, they are expected as therapeutic agents for some kinds of cancers which show resistance against existing anticancer agents.
Test Example 1:
1) Test Compounds The dose levels are expressed in terms of YM155, the cationic moiety of the drug substance. Docetaxel hydrate (Taxotere INJECTION) was purchased from Sanofi-Aventis Pharma Ltd. (West Lavel, FRA) and used as docetaxel.
2) Preparation of Test Compounds YM155 was dissolved in and diluted with physiological saline in order to prepare dosing solutions (concentrations calculated using the following formulation: dose x mean body weight for each group / daily release volume).
These solutions were prepared immediately before the implantation of an osmotic pump (Alzet model 1007D Micro-Osmotic Pump, DURECT Co., CA, USA) into the test subjects. The solutions were then loaded into the pump. Docetaxel was diluted with physiological saline to prepare 2mg/mL solutions immediately before administration.
3) Cells The human lung carcinoma cell line Calu 6 (HTB-56, Lot No. 208280) was obtained from American Type Culture Collection (VA, USA). The cells were cultured at 37 C in a 5% CO2 atmosphere in RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum. The cells were collected with trypsin, suspended in PBS at 6x 107cells/mL, and then mixed with an equivalent volume of Matrigel Basement Membrane Matrix (Becton Dickinson Co., Bedford, MA, USA).
[00241 4) Animals Five-week-old male nude mice (CAnN.Cg-Foxnlnu/CrlCrlj(nu/nu)) were purchased from Charles River Laboratories Japan, Inc (Kanagawa, Japan). They were maintained on a standard diet and water throughout the experiments under specific pathogen-free conditions. The cells were cultured in vitro and 3 x106 cells/0.1 mL/mouse were grafted subcutaneously into the flank of 6-week-old nude mice.
The mice with tumor volumes (lengthxwidth2x0.5) of 97.3 to 182.7 mm3 were divided into groups. This was done using SAS software in order to min;m;ze intragroup and intergroup tumor volume variation.
5) Administration and Measurement The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2 mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxel 20 mg/kg/day (iv bolus on day 0, 4, and 8) Combination group YM155 2 mg/kg/day + Docetaxe120 mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 0, and iv bolus injection of physiological saline on days 0, 4 and 8. The YM155 group received a 7-day sc continuous infusion of YM155 at 2 mg/kg/day starting on day 0, and iv bolus injection of physiological saline on days 0, 4 and 8. The docetaxel group received iv bolus injection of docetaxel at 20 mg/10 mL/kg on days 0, 4 and 8, as well as a 7-day sc continuous infusion of physiological saline starting on day 0. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
Body weight and tumor diameter were measured every 3-4 days using calipers, and tumor volume was determined by calculating the volume of an ellipsoid using the formula: lengthxwidth2x0.5. Antitumor activities are expressed as percent inhibition of tumor growth (% inh) and percent regression of the tumor (% reg). The percent inhibition of tumor growth on day 35 was calculated for each group using the following formula: 100 x[1-{(mean tumor volume of each group on day 35) - (mean tumor volume of each group on day 0)} /{(mean tumor volume of the control group on day 35) - (mean tumor volume of the control group on day 0)}]. The percent regression of the tumor was calculated for all groups with observed tumor regression, using the following formula: 100 x{1-(mean tumor volume of each group on day 35) / (mean tumor volume of each group on day 0)}. The number of Complete Regressions (CRs) in all groups were checked during the experimental period. The CR is defined by instances in which the tumor burden falls bellow the limit of palpation.
[0025] 6) Statistical Analysis Values are expressed as the mean the standard error of the mean (SEM).
Tumor volume and body weight on day 35 were compared between each single compound group and combination group using the Student's t-test. P values of less than 5% are considered significant. SAS software was used for data processing.
7) RESULTS
YM155 was administered concomitantly with docetaxel, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day and docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression in all cases on day 35 (Table 2 and Figure 1-(a)). YM155 treatment alone inhibited tumor growth by 99% on day 35. Docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 52% on day 35. During the weeks of observation, YM155 or docetaxel treatment group showed tumor regression during the first two weeks which was followed by successive tumor regrowth during the last few weeks. On the other hand, YM155 in combination with docetaxel showed complete regression of the tumors in all cases. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(d)).
[0026] [Table 21 Tumor Volume (mm3) Body Weight (g) Antitumor Activity Number of Treatment Groups Complete day 0 day 35 day 35 (% inh l% reg) Regressions Vehicle Control 120.9 7.0 2848.0 185.1 26.56 0.56 --- 0/8 YM155 121.4 6.9 142.3 16.9 26.13 0.56 99% 0/8 Docetaxel 121.4 7.0 58.0 20.4 24.95 0.54 >100% / 52% 0/8 YM155 + Docetaxel 121.1 7.2 0.0 0.0 '="~ 24.11 0.66 "=NS >100% / 100% 8/8 Values are expressed as the mean SEM (n=8). *: P<0.05, a significant difference of the combination group versus Docetaxel group. ##: F<0.01 and #:
P<0.05, significant. differences of the combination group versus YM155 group.
N.S.: no significance from Docetaxel group (Student's t-test).
8) DISCUSSION
Results of this study indicate that YM155 significantly potentiate the anti-tumor activity of docetaxel without an increase in systemic toxicity, which is evidenced by overt symptoms such as body weight loss. The results also suggest that YM155 in combination with docetaxel is tolerated by mice, and that makes a strong combination for the treatment of cancer.
[0027] Test Example 2 The following study was conducted in the same way as Test Example 1 except for the administration timing.
A) The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxe120mg/kg/day (iv bolus on day 7, 11, and 15) Combination group YM155 2mg/kg/day - Docetaxe120mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 0, and iv bolus injection of physiological saline on days 7, lland 15. The YM155 group received a 7-day sc continuous infusion of YM155 at 2mg/kg/day starting on day 0 and iv bolus injection of physiological saline on days 7, 11 and 15. The docetaxel group received iv bolus injection of docetaxel at 20mg/lOmL/kg on days 7, 11 and 15, as well as a 7-day sc continuous infusion of physiological saline starting on day 0. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
RESULTS
Docetaxel was administered following the administration of YM155, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day with docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression by 99% on day 35 (Table 3 and Figure 1-(c)). YM155 treatment alone inhibited tumor growth by 99% on day 35. docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 10% on day 35. During the 5 weeks of observation, YM155 or docetaxel group showed tumor regression during the first two weeks which was followed by successive tumor regrowth during the last few weeks. On the other hand, the combination group of YM155 with docetaxel showed tumor regression in all cases and complete regression of the tumors in 7 cases of 8 cases, and anticancer effect was significantly (P<0.01) potentiated as compared to each single compound treatment group. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(f)).
,[0028] [Table 31 Titmor Volume (mm3) Body Weight (g) Antitumor Activity Treatment Groups Number of CRs day 0 day 35 day 35 (% inh l% reg ) Vehicle Control 208.5 18.6 4237.0 545.7 25.88 0.70 --- 0/8 YM155 208.5 18.6 251.8 50.7 26.25 0.25 99% /- 0/8 Docetaxel 209.1 18.3 188.8 29.1 21.03 0.94 >100%/ 10% 0/8 YM155-+Docetaxel 208.6 18.1 1.3 1.3 "=* 24.13 0.78'=* >100%/ 99% 7/8 Values are expressed as the mean SEM (n=8). **: F<0.01 and P<0.05, significant differences of the combination group versus Docetaxel group. #:
P<0.05, significant differences of the combination group versus YM155 group.
(Student's t-test).
[0029] B) The first day of administration was designated day 0, and observation continued until day 35. Each group (n=8) was treated as follows.
Vehicle control group Vehicle YM155 group YM155 2mg/kg/day (7-day sc continuous infusion) Docetaxel group Docetaxe120mg/kg/day (iv bolus on day 0, 4, and 8) Combination group Docetaxe120mg/kg/day - YM155 2mg/kg/day For 7-day sc continuous infusion, an osmotic pump containing either YM155 or physiological saline, was implanted in the dorsum of each animal while under anesthesia. The vehicle control group received a 7-day sc continuous infusion of physiological saline starting on day 8, and iv bolus injection of physiological saline on days 0, 4 and 8. The YM155 group received a 7-day sc continuous infusion of YM155 at 2 mg/kg/day starting on day 8, and iv bolus injection of physiological saline on days 0, 4 and 8. The docetaxel group received iv bolus injection of docetaxel at 20 mg/10 mL/kg on days 0, 4 and 8, as well as a 7-day sc continuous infusion of physiological saline starting on day 8. The combination group received both compounds instead of the vehicle, similarly to the YM155 and docetaxel groups.
RESULTS
YM155 was administered following the administration of Docetaxel, and the anti-tumor activity was examined. The combination of YM155 at 2 mg/kg/day with docetaxel at 20 mg/kg/day completely inhibited tumor growth (>100%), and induced complete regression by 97% on day 35 (Table 4 and Figure 1-(b)). YM155 treatment alone inhibited tumor growth by 61% on day 35. Docetaxel also exhibited complete inhibition (>100%) of tumor growth, and induced tumor regression by 68%
on day 35. During the 5 weeks of observation, YM155 or docetaxel treatment group showed tumor regrowth during the last few weeks. On the other hand, YM155 in combination with docetaxel showed complete regression of the tumors in three cases, and anticancer effect was significantly (P<0.01) potentiated as compared to each single compound treatment group on day 35. No statistically significant decrease in body weight was observed in the combination group as compared to docetaxel group (Figure 1-(e)).
[0030] [Table 4]
Tumor Volume (mm3) Body Weight (g) Antitumor Activity Treatment Groups Number of CRs day 0 day 35 day 35 (% inh l% reg) Vehicle Control 207.7 23.5 3380.8 325.4 24.33 0.85 --- 0/8 YM155 206.9 21.8 1437.5 225.5 24.80 1.01 61 %/- 0/8 Docetaxel 210.0 22.6 67.2 15.1 23.84 1.01 >100%/ 68% 0/8 Docetaxel -YM155 210.1 20.4 5.5 1.7 ","" 25.74 1.13 -1- >100% / 97% 3/8 Values are expressed as the mean SEM (n=8). **: F<0.01, a significant difference of the combination group versus Docetaxel group. ##: .F<0.01, a significant difference of the combination group versus YM155 group. N.S.: no significance from Docetaxel group (Student's ftest).
[0031] Test Example 3 The study was conducted in the same way as Test Example 1, except that the listed agents in Table 5 were used instead of Docetaxel according to the following dosage regimen.
[Table 5) Anticancer Agent Dosage Regimen Result Carboplatin CBDCA 60 mg/kg/day i.v. (day 0, 1) Fig. 2-(a) & (b) Cisplatin CDDP 3 mg/kg/day i.v. (day 0-4, 7-11) Fig. 2-(c) & (d) Gemcitabine GEM 200 mg/kg/day i.v. (day 0,3,6) Fig. 3-(a) & (b) Vinorelbine VNR 10 mg/kg/day i.v. (day 0, 7) Fig. 3-(c) & (d) Doxorubicin DXR 10 mg/kg/day i.v. (day 0, 7) Fig. 4-(a) & (b) Irinotecan CPT- 11 60 mg/kg/day i.v. (day 0-4) Fig. 4-(c) & (d) Paclitaxel TXL 10-15 mg/kg/day i.v. (day 0-4) Fig. 5-(a) & (b) (In the Table 5, i.v. means intravenous administration, for example, (day 0, 1) means once-a-day administration at the initial day of administration (day 0) and at the Ist day (day 1); (day 0-4) means once-a-day administration from the initial day of administration (day 0) to the 4th day (day 4), respectively.) Results were shown in Figure 2 to 5. In the figures, values are expressed as the mean f SEM (n=8). * P<0.05 versus the anticancer agent group, ##:
P<0.01 versus YM155 group, #: P<0.05 versus YM155 group, N.S.: no significance from YM155 group and the anticancer agent group respectively (Student's iftest).
The respective anticancer agents were purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
(0032] Test Example 4 The study was conducted in the same way as Test Example 1, except that Dacarbazine was used instead of Docetaxel and Melanoma A375 cells were used instead of Calu 6 cells according to the following dosage regimen (n=8).
Results were shown in Figure 6.
YM155 group YM155 3 mg/kg/day (7-day sc continuous infusion) Dacarbazine (DTIC) group Dacarbazine 200 mg/kg/day, i.v.(day0-5) Combination group YM155 3 mg/kg/day (7-day sc continuous infusion) +
Dacarbazine 200 mg/kg, i.v.(day0-5) Dacarbazine was purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
[0033] Test Example 5 The study was conducted in the same way as Test Example 1, except that a combination therapy R-ICE(RICE) or Rituximab(RTX) was used instead of Docetaxel, and lymphoma WSU-DLCL-2 cells were used instead of Calu 6 cells according to the following dosage regimen.
YM155 group YM155 1 mg/kg/day (7-day sc continuous infusion) RICE group RTX 50 mg/kg, i.v. (day 0) + (IFM 200 mg/kg+ETP 10 mg/kg), i.v. (day 1,2 and 3) + CBDCA 30 mg/kg, i.v. (day 1) YM155+RICE group YM155 1 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v. (day 0) + (IFM 200 mg/kg + ETP 10 mg/kg), i.v. (day 1,2 and 3) + CBDCA 30 mg/kg, i.v (day 1).
YM155+RTX group YM155 1 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v.(day 0).
Rituximab(RTX), carboplatin(CBDCA), ifosfamide (IFM), and etoposide (ETP) were purchased as commercially available products, and prepared according to the procedure directed in package inserts to use in the tests.
Results were shown in Figure 7. In the figures, values are expressed as the mean f SEM (n=6). **: P<0.01 versus RICE or RTX group, *: P'<0.05 versus RICE or RTX group, ##: P<0.01 versus YM155 group, N.S.: no significance from YM155 group and RICE or RTX group respectively (Student's t-test).
YM155 in combination with RICE showed complete regression of the tumors in one case, and YM155 in combination with RTX showed complete regression of the tumors in two cases.
The preliminary study was done by using the method similar to the above-mentioned YM155+RICE group, but a combination therapy R-DHAP was used instead of a combination therapy R-ICE, wherein R-DHAP was consisting of rituximab (50mg/kg i.v., day 0 and 2), cisplatin (5mg/kg, i.v., day 2), cytarabin (70mg/kg, i.v., day 4). The tumor volume was significantly (P<0.01) reduced in the combination group as compared to R-DHAP group on day 18.
[0034] Test Example 6 The study was conducted in the same way as Test Example 5 according to the following dosage regimen.
YM155 group: YM155 2 mg/kg/day (7-day sc continuous infusion) RICE group : RTX 50 mg/kg, i.v. (day 6 and 8) + (IFM 400 mg/kg +
CBDCA 30 mg/kg), i.v (day 9) + ETP 10 mg/kg, i.v (day 8, 9 and 1.0) YM155+RICE group YIVM155 2 mg/kg/day (7-day sc continuous infusion) +
RTX 50 mg/kg, i.v. (day 6 and 8) + (IFM 400 mg/kg + CBDCA 30 mg/kg), i.v. (day 9) + ETP 10 mg/kg, i.v. (day 8, 9 and 10) Results were shown in table 6. In the table, values are expressed as the mean SEM (n=8, RICE group : n=6). **: P<0.01 versus RICE group, ##: F<0.01 versus YM155 group, N.S.: no significance from RICE group (Student's t-test).
YM155 in combination with RICE showed complete regression of the tumors in 6 cases of 8 cases.
[0035] (Table 61 Treatment Groups Tumor Volume (mm3) Body Weight (g) Antitumor Activity Number of day 0 day 28 day 28 (% inh l% reg) CRs Vehicle Control 404.4 14.5 2131.5 276.6 29.02 0.38 --- 0/8 YM155 405.1 13.8 1181.3 174.7 28.81 0.23 45% 0/8 RICE 404.2 13.0 1356.0 371.7 29.54 0.51 56% 0/6 YM155 ---> RICE 404.7 12.6 17.6 11.5 **= ## 28.55 0.26N.s. >100% / 96%
INDUSTRIAL APPLICABILITY
[00361 The pharmaceutical composition comprising YM155 as an active ingredient for treatment of a cancer in a combined therapy with one or more existing anticancer agents, in which the inhibitory action of YM155 on expression of survivin works synergistically with the anticancer effect of the existing anticancer agent, affords a high therapeutic effect for cancers and is useful in treatment of a variety of cancers to which existing anticancer agents are applied, accordingly. Thus, the pharmaceutical composition of the invention is useful in treatment of cancers, preferably all solid cancers and lymphomas, particularly skin cancer, bladder cancer, breast cancer, uterine cancer, ovary cancer, prostate cancer, lung cancer, colon cancer, pancreas cancer, renal cancer, gastric cancer, and the like. Particularly, they are expected as therapeutic agents for some kinds of cancers which show resistance against existing anticancer agents.
Claims (15)
1. A pharmaceutical composition comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H
-naphtho[2,3-d)imidazol-3-ium bromide as an active ingredient, for treating cancer in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.
-naphtho[2,3-d)imidazol-3-ium bromide as an active ingredient, for treating cancer in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.
2. The composition as claimed in claim 1, wherein the combined therapy comprises the use of docetaxel or paclitaxel.
3. The composition as claimed in claim 2, wherein the combined therapy comprises the use of docetaxel.
4. The composition as claimed in claim 3, wherein the composition is for treating hormone-resistant prostate cancer.
5. The composition as claimed in claim 1, wherein composition is for treating lung cancer and the combined therapy comprises the use of one or more agents selected from docetaxel, paclitaxel, carboplatin, cisplatin and gemcitabine.
6. The composition as claimed in claim 1, wherein the combined therapy comprises the use of rituximab.
7. The composition as claimed in claim 1, wherein the combined therapy comprises the use of a combination therapy selected from R-ICE and R-DHAP.
8. The composition as claimed in claim 7, wherein the combined therapy comprises the use of a combination therapy R-ICE.
9. The composition as claimed in claim 6 or 7, wherein the composition is for treating lymphoma.
The composition as claimed in any of Claims 1 to 9, wherein the composition is a formulation for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 1 -
The composition as claimed in any of Claims 1 to 9, wherein the composition is a formulation for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 1 -
10 mg/m2/day continuously for a period of 4 - 14 days.
11. A composition as (1) 10, wherein the formulation is for administering 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho2,3-d]imidazol-3-ium bromide intravenously by infusion at a dose of 3 - 8 mg/m2/day continuously for 7 days, followed by drug holidays of 14 days, which administration cycle as one cycle is repeated depending on the conditions.
12. Use of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide for production of a medicament for treating cancer, wherein the medicament is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.
13. An agent for cancer treatment comprising as an active ingredient 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide, wherein the agent is used in a combined therapy which comprises the use of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.
14. A potentiator of anticancer effect of i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents, wherein the potentiator comprises 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide as an active ingredient.
15. A kit comprising at least one cycle dosage of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-nap htho[2,3-d]imidazol-3-ium bromide and i) one or more anticancer agents selected from the group consisting of carboplatin, cisplatin, paclitaxel, vinorelbine, gemcitabine, irinotecan, docetaxel, doxorubicin, dacarbazine and rituximab, or ii) anticancer agents for a combination therapy selected from R-ICE consisting of rituximab, ifosfamide, carboplatin and etoposide, and R-DHAP consisting of rituximab, cytarabine and cisplatin as anticancer agents.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88280906P | 2006-12-29 | 2006-12-29 | |
| US60/882809 | 2006-12-29 | ||
| US95077107P | 2007-07-19 | 2007-07-19 | |
| US60/950771 | 2007-07-19 | ||
| PCT/JP2007/075277 WO2008081927A1 (en) | 2006-12-29 | 2007-12-28 | Method for treating cancer using anticancer agent in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2672933A1 true CA2672933A1 (en) | 2008-07-10 |
Family
ID=39588607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002672933A Abandoned CA2672933A1 (en) | 2006-12-29 | 2007-12-28 | Method of treating cancer by a combined therapy of anticancer agents |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7618992B2 (en) |
| EP (2) | EP2127652B1 (en) |
| JP (2) | JP4788774B2 (en) |
| CA (1) | CA2672933A1 (en) |
| DK (1) | DK2127652T3 (en) |
| ES (1) | ES2409755T3 (en) |
| PL (1) | PL2127652T3 (en) |
| PT (1) | PT2127652E (en) |
| WO (1) | WO2008081927A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| GB2471065A (en) * | 2009-06-10 | 2010-12-22 | Univ Sheffield | Modulator of claspin for treatment of cell proliferative disorder |
| JP2011001315A (en) | 2009-06-19 | 2011-01-06 | Cellex Corp | Immunotherapy agent for pancreatic cancer |
| CZ302618B6 (en) | 2009-09-10 | 2011-08-03 | Univerzita Palackého | Platinum cyclobutane-1,1-dicarboxylate complexes with N6-benzyladenine derivatives, process of their preparation and use of these complexes as medicaments in antitumor therapy |
| CA2742342A1 (en) * | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| WO2012167099A1 (en) * | 2011-06-01 | 2012-12-06 | Baylor College Of Medicine | Biomarkers and therapy for cancer |
| US8871189B2 (en) * | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| WO2013148649A1 (en) | 2012-03-26 | 2013-10-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| US9242000B2 (en) * | 2012-10-18 | 2016-01-26 | The Regents Of The University Of California | Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them |
| WO2014142220A1 (en) * | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | Anti-tumor agent |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| WO2016040294A2 (en) | 2014-09-09 | 2016-03-17 | Janssen Biotech, Inc. | Combination therapies with anti-cd38 antibodies |
| NZ732753A (en) | 2014-12-04 | 2024-08-30 | Janssen Biotech Inc | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| KR102602754B1 (en) | 2015-05-20 | 2023-11-14 | 얀센 바이오테크 인코포레이티드 | Anti-CD38 antibodies for treating light chain amyloidosis and other CD38-positive hematological malignancies |
| ES2890783T3 (en) | 2015-06-22 | 2022-01-24 | Janssen Biotech Inc | Combination therapies for hematologic malignancies with anti-CD38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| CN108472369A (en) | 2015-11-03 | 2018-08-31 | 詹森生物科技公司 | The subcutaneous preparations and application thereof of 8 antibody of AntiCD3 McAb |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| MA50514A (en) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | HIGH-RISK MULTIPLE MYELOMA TREATMENT METHODS |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| WO2020205739A1 (en) * | 2019-03-31 | 2020-10-08 | The Trustees Of The University Of Pennsylvania | 'smart' hydrogel for the radiosensitization and sustained delivery of therapeutics triggered by irradiation |
| WO2020227682A1 (en) * | 2019-05-08 | 2020-11-12 | Children's Medical Center Corporation | Treating cancer |
| WO2021155580A1 (en) * | 2020-02-07 | 2021-08-12 | Cothera Bioscience, Inc. | Combination therapies and biomarkers for treating cancer |
| WO2023039803A1 (en) * | 2021-09-16 | 2023-03-23 | Xiang Li | Androgen receptor biomarkers for cancer therapy |
| WO2023092394A1 (en) * | 2021-11-25 | 2023-06-01 | Guo Dagang | Methods and compositions for treating ewing family of tumors |
| WO2023219948A1 (en) * | 2022-05-08 | 2023-11-16 | The Regents Of The University Of Colorado, A Body Corporate | Therapeutic biomaterial that attenuates the foreign body response |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| AU2001232286A1 (en) | 2000-02-15 | 2001-08-27 | Yamanouchi Pharmaceutical Co..Ltd. | Fused imidazolium derivatives |
| JP3634328B2 (en) | 2001-08-10 | 2005-03-30 | 山之内製薬株式会社 | Pharmaceutical composition comprising a condensed imidazolium derivative |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| US20060223831A1 (en) | 2003-04-15 | 2006-10-05 | Isao Kinoyama | Bromide and its crystal |
| US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
-
2007
- 2007-12-27 US US11/965,476 patent/US7618992B2/en not_active Expired - Fee Related
- 2007-12-28 WO PCT/JP2007/075277 patent/WO2008081927A1/en active Application Filing
- 2007-12-28 PT PT78604808T patent/PT2127652E/en unknown
- 2007-12-28 JP JP2008552180A patent/JP4788774B2/en not_active Expired - Fee Related
- 2007-12-28 PL PL07860480T patent/PL2127652T3/en unknown
- 2007-12-28 CA CA002672933A patent/CA2672933A1/en not_active Abandoned
- 2007-12-28 EP EP07860480.8A patent/EP2127652B1/en not_active Not-in-force
- 2007-12-28 EP EP13161034.7A patent/EP2609920A1/en not_active Withdrawn
- 2007-12-28 ES ES07860480T patent/ES2409755T3/en active Active
- 2007-12-28 DK DK07860480.8T patent/DK2127652T3/en active
-
2009
- 2009-06-29 US US12/493,577 patent/US8003105B2/en not_active Ceased
-
2011
- 2011-05-31 JP JP2011121330A patent/JP2011168619A/en active Pending
-
2013
- 2013-08-22 US US13/973,071 patent/USRE45105E1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| USRE45105E1 (en) | 2014-09-02 |
| US20080166344A1 (en) | 2008-07-10 |
| EP2127652B1 (en) | 2013-05-15 |
| US8003105B2 (en) | 2011-08-23 |
| EP2609920A1 (en) | 2013-07-03 |
| JP2011168619A (en) | 2011-09-01 |
| EP2127652A4 (en) | 2010-04-07 |
| JPWO2008081927A1 (en) | 2010-04-30 |
| JP4788774B2 (en) | 2011-10-05 |
| WO2008081927A1 (en) | 2008-07-10 |
| ES2409755T3 (en) | 2013-06-27 |
| PL2127652T3 (en) | 2013-10-31 |
| EP2127652A1 (en) | 2009-12-02 |
| US20090263390A1 (en) | 2009-10-22 |
| US7618992B2 (en) | 2009-11-17 |
| PT2127652E (en) | 2013-07-08 |
| DK2127652T3 (en) | 2013-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| USRE45105E1 (en) | Method of treating cancer by co-administration of anticancer agents | |
| Rudin et al. | A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer | |
| JP7194022B2 (en) | Combination therapy with Notch inhibitors and PD-1 or PD-L1 inhibitors | |
| CZ20013614A3 (en) | Therapeutic pharmaceutical preparation | |
| KR20010075348A (en) | Chemotherapy of Cancer with Acetyldinaline in Combination with Gemcitabine, Capecitabine or Cisplatin | |
| AU2013402794A1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| WO2014142220A1 (en) | Anti-tumor agent | |
| MX2010010621A (en) | Method and compositions for treatment of cancer. | |
| EP3988175A1 (en) | Method for treating malignant tumor | |
| JP2019508433A (en) | Combination therapy using LIV1-ADC and chemotherapeutic agents | |
| JP2016528217A (en) | Treatment of pancreatic cancer using a combination of hypoxia activated prodrug and taxane | |
| JP5416327B2 (en) | Drug for preventing or reducing neurotoxicity caused by taxane | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| EP3456354A1 (en) | New anti-malignant tumor agent based on specificity of cancer cell metabolism | |
| Gelmon et al. | A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers | |
| WO2012106379A1 (en) | Sensitization of cancer cells to treatment | |
| JP2008514721A (en) | Method of treatment | |
| KR102032933B1 (en) | Pharmaceutical composition for treatment or palliation of elderly or end-stage cancer patient | |
| KR101847252B1 (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| JP2005511663A5 (en) | ||
| MXPA04006822A (en) | Combinations comprising epothilones and anti-metabolites. | |
| JP7311177B2 (en) | Combined use of A-NOR-5α androstane drugs with anticancer drugs | |
| JP2021063014A (en) | Leukemia therapeutic agent | |
| JP2003055208A (en) | Combination chemotherapy | |
| RU2816126C2 (en) | Method of treating malignant tumour |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20160718 |